Loading...
XNAS
CALC
Market cap15mUSD
Jul 09, Last price  
0.95USD
1D
5.54%
1Q
53.76%
IPO
-99.58%
Name

CalciMedica Inc

Chart & Performance

D1W1MN
XNAS:CALC chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
694.98%
Rev. gr., 5y
%
Revenues
0k
Net income
-30m
L+115.78%
-28,378,000-37,037,000-27,531,000-35,821,000-7,824,000-34,357,000-13,700,000-29,562,000
CFO
-21m
L+0.15%
-28,216,000-31,215,000-32,064,000-31,500,000-11,757,000-25,730,000-21,146,000-21,178,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
IPO date
Sep 25, 2020
Employees
8
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT